CD4 and Hepatitis: Hence, we observed no hepatitis in the four valganciclovir-treated patients, whereas 15 of 17 (88.2%) CMV IgG+ CD4+ TEM≥16% patients treated with αPD-1/αCTLA-4 and no valganciclovir prophylaxis developed clinical hepatitis (Fig. 9b).